FBRX
Forte Biosciences, Inc.NASDAQHealthcare$25.58+2.90%ClosedMarket Cap: $320.4M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
63.80
P/S
0.00
EV/EBITDA
-3.60
DCF Value
$0.47
FCF Yield
-15.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-98.4%
ROA
-83.8%
ROIC
-113.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-24.8M | $-1.39 |
| FY 2025 | $0.00 | $-69.4M | $-4.71 |
| Q3 2025 | $0.00 | $-17.7M | $-0.99 |
| Q2 2025 | $0.00 | $-11.2M | $-0.96 |
Analyst Ratings
View AllChardan CapitalBuy
2025-11-17Chardan CapitalBuy
2025-08-15Chardan CapitalBuy
2025-06-24Trading Activity
Insider Trades
View AllWagner Paul A.director, officer: SEE REMARKS
SellFri Apr 03
Wagner Paul A.director, officer: SEE REMARKS
SellFri Apr 03
Riley Antony Aofficer: CHIEF FINANCIAL OFFICER
SellFri Apr 03
Riley Antony Aofficer: CHIEF FINANCIAL OFFICER
SellFri Apr 03
Riley Antony Aofficer: CHIEF FINANCIAL OFFICER
SellTue Jan 13
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
3.23
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.